Indoco Remedies
Ticker > Company >

Indoco Remedies share price

Indoco Remedies Ltd.

NSE: INDOCO BSE: 532612 SECTOR: Pharmaceuticals & Drugs  54k   139   14

339.95
+5.10 (1.52%)
NSE: 20 Dec 04:02 PM

Price Summary

Today's High

₹ 346

Today's Low

₹ 325.45

52 Week High

₹ 415

52 Week Low

₹ 286.6

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 3133.73 Cr.

Enterprise Value

₹ 3613.64 Cr.

No. of Shares

9.22 Cr.

P/E

36.73

P/B

2.75

Face Value

₹ 2

Div. Yield

0.44 %

Book Value (TTM)

₹  123.84

CASH

₹ 16.94 Cr.

DEBT

₹ 496.85 Cr.

Promoter Holding

58.75 %

EPS (TTM)

₹  9.25

Sales Growth

7.45%

ROE

10.85 %

ROCE

12.89%

Profit Growth

-17.49 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Indoco Remedies Ltd.

SPADE SURGE-RADIUS WARREN WARREN-EXCEL SPERA

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year7.45%
3 Year13.02%
5 Year13.1%

Profit Growth

1 Year-17.49%
3 Year8.08%
5 Year112.23%

ROE%

1 Year10.85%
3 Year14.66%
5 Year12.07%

ROCE %

1 Year12.89%
3 Year17.87%
5 Year15%

Debt/Equity

0.4424

Price to Cash Flow

17.73

Interest Cover Ratio

5.054

CFO/PAT (5 Yr. Avg.)

1.38701397165832

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 58.75 0.00
Jun 2024 58.75 0.00
Mar 2024 58.72 0.00
Dec 2023 58.74 0.00
Sep 2023 58.74 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 60.2263 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.38701397165832.
  • The company has a high promoter holding of 58.75%.

 Limitations

  • The company has shown a poor profit growth of 8.0783194342648% for the Past 3 years.
  • The company has shown a poor revenue growth of 13.0246448541301% for the Past 3 years.
  • Company has contingent liabilities of 347.9011 Cr.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 473.39 449.05 445.49 401.43 396.53
Total Expenditure 400.97 383.76 388.13 349.86 343.66
Operating Profit 72.42 65.29 57.36 51.57 52.87
Other Income 1.12 2.93 4.05 3.52 4.2
Interest 8.1 10.03 10.91 11.88 14.77
Depreciation 21.41 22.97 23.73 23.7 24.92
Exceptional Items 0 -8.2 19.73 0 0
Profit Before Tax 44.03 27.02 46.5 19.51 17.38
Tax 10.89 7.01 8.94 4.56 4.59
Profit After Tax 33.14 20.01 37.56 14.95 12.79
Adjusted EPS (Rs) 3.6 2.17 4.07 1.62 1.39

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 1105.99 1240.3 1539.72 1666.69 1790.81
Total Expenditure 985.01 1022.67 1213.81 1381.85 1540.71
Operating Profit 120.98 217.63 325.91 284.84 250.1
Other Income 4.79 9.05 6.71 2.62 17.38
Interest 26.25 22.22 17.43 25.27 37.8
Depreciation 70.81 73.12 78.95 70.6 87.98
Exceptional Items 0 0 0 0 11.53
Profit Before Tax 28.71 131.35 236.23 191.59 153.23
Tax 4.46 38.96 81.71 50.23 36.58
Net Profit 24.25 92.39 154.52 141.36 116.64
Adjusted EPS (Rs.) 2.63 10.03 16.77 15.34 12.65

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 18.43 18.43 18.43 18.43 18.44
Total Reserves 661.73 750.5 885.87 1008.59 1108.18
Borrowings 96.93 96.94 95.88 143.5 203.6
Other N/C liabilities 3.98 61.36 60.68 61.91 68.14
Current liabilities 459.17 408.54 519.93 483.21 595.03
Total Liabilities 1240.24 1335.76 1580.8 1715.64 1993.38
Assets
Net Block 589.62 569.91 554.98 661.46 732.34
Capital WIP 7.32 25.12 52.82 54.36 92.5
Intangible WIP 43.38 42.98 68.72 58.21 21.94
Investments 2.45 2.45 2.46 18.9 51.96
Loans & Advances 34.02 71.29 33.68 52.03 154.87
Other N/C Assets 1.68 2.05 2.13 2.25 6.78
Current Assets 561.76 621.95 866.01 868.44 932.99
Total Assets 1240.24 1335.76 1580.8 1715.64 1993.38
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 28.71 131.35 236.23 191.59 141.7
Adjustment 99.51 109.71 87.12 120.88 130.08
Changes in Assets & Liabilities -1.65 -139.14 -108.81 -72.29 -77.42
Tax Paid -3.92 -19.75 -40.99 -61.38 -29.1
Operating Cash Flow 122.66 82.17 173.55 178.79 176.78
Investing Cash Flow -55.95 -66.7 -121.41 -208.51 -301.7
Financing Cash Flow -63.95 -29.83 -44.37 22.81 122.4
Net Cash Flow 2.76 -14.35 7.77 -6.91 -2.52

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 58.74 58.74 58.72 58.75 58.75
kare aruna suresh 5.20 5.20 5.20 5.20 5.20
kare suresh govind 4.41 4.41 4.40 4.40 4.40
madhura suresh kare 5.64 5.64 5.64 5.65 5.65
mahika milind panandikar 0.01 0.01 0.01 0.01 0.01
megh milind panandikar 0.01 0.01 0.01 0.01 0.01
milind s panandikar 0.01 0.01 0.01 0.01 0.01
panandikar aditi milind 6.07 6.07 6.07 6.08 6.08
pratima ajit vaidya 0.03 0.03 0.03 0.03 0.03
rohan anup ramani 0.01 0.01 0.01 0.01 0.01
shanteri investment pvt l... 17.12 17.12 17.11 17.11 17.11
sharda ramnath kare 0.04 0.04 0.04 0.04 0.04
spa holdings pvt ltd 19.90 19.90 19.89 19.89 19.89
sudha m pai 0.01 0.01 0.01 0.01 0.01
suresh govind kare huf (k... - - - - 0.30
suresh govind kare (huf) ... - - - 0.30 -
suresh govind kare huf ... 0.30 0.30 0.30 - -
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 41.26 41.26 41.28 41.25 41.25
dsp healthcare fund 1.37 1.51 1.84 2.27 2.52
franklin india smaller co... 1.48 1.48 1.48 1.48 1.48
hdfc trustee company ltd.... - - - - 1.67
icici prudential smallcap... 4.42 2.21 1.91 1.79 1.14
independent director 0.02 - 0.02 - 0.01
investor education and pr... 0.11 - 0.11 0.11 0.11
llp 0.10 0.06 0.05 0.07 0.09
mangeshi investment priva... 1.27 1.27 1.27 1.27 1.27
nippon life india trustee... 4.97 4.97 4.97 4.97 4.97
quant mutual fund - quant... - - - 4.56 4.56
hdfc trustee company ltd ... 1.32 1.63 1.63 1.45 -
quant mutual fund-quant s... - 4.45 4.56 - -
uti healthcare fund 1.18 1.07 1.05 - -
investor education and pr... - 0.11 - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Indoco Remedies informs about disclosure 17 Dec, 3:17 PM Indoco Remedies gets warning letter for Goa facility 17 Dec, 2:25 PM Indoco Remedies informs about investors meet 10 Dec, 5:18 PM Indoco Remedies informs about disclosure 3 Dec, 10:27 AM Indoco Remedies enters into strategic distribution partnership with Clarity Pharma, UK 2 Dec, 5:34 PM Indoco Remedies informs about disclosure 27 Nov, 5:39 PM Indoco Remedies informs about disclosure 19 Nov, 5:32 PM Indoco Remedies gets final ANDA approval from USFDA for Varenicline Tablets 30 Oct, 2:26 PM Indoco Remedies - Quaterly Results 24 Oct, 12:29 PM Indoco Remedies - Quaterly Results 24 Oct, 12:29 PM Indoco Remedies - Quaterly Results 24 Oct, 12:29 PM Indoco Remedies gets USFDA’s approval for Cetirizine Hydrochloride Tablets 4 Oct, 3:08 PM Indoco Remedies informs about press release 4 Oct, 1:41 PM Indoco Remedies informs about disclosure 26 Aug, 5:27 PM Indoco Remedies gets USFDA’s final approval for Lofexidine Tablets 21 Aug, 2:58 PM USFDA inspects Indoco Remedies’ manufacturing facilities in Goa 27 Jul, 3:55 PM Indoco Remedies informs about disclosure 26 Jul, 11:07 AM Indoco Remedies informs about press release 24 Jul, 5:00 PM Indoco Remedies informs about outcome of board meeting 23 Jul, 4:58 PM Indoco Remedies reports 92% fall in Q1 consolidated net profit 23 Jul, 3:55 PM Indoco Remedies - Quaterly Results 23 Jul, 11:13 AM Indoco Remedies - Quaterly Results 23 Jul, 11:13 AM Indoco Remedies - Quaterly Results 23 Jul, 11:13 AM Indoco Remedies informs about board meeting 10 Jul, 4:57 PM Indoco Remedies informs about disclosures 10 Jun, 2:41 PM Indoco Remedies informs about press release 6 Jun, 4:53 PM Indoco Remedies gets USFDA’s tentative approval for Canagliflozin and Metformin Hydrochloride tablets 6 Jun, 3:14 PM Indoco Remedies gets USFDA’s final approval for Pregabalin capsules 22 May, 10:41 AM Indoco Remedies informs about earnings call transcript 21 May, 12:56 PM USFDA completes inspection at Indoco Remedies’ Kilo Lab facility, IAS division 16 May, 4:30 PM Indoco Remedies - Quaterly Results 16 May, 2:44 PM Indoco Remedies - Quaterly Results 16 May, 2:44 PM Indoco Remedies - Quaterly Results 16 May, 2:44 PM Indoco Remedies informs about corporate guarantee 5 Apr, 4:52 PM Indoco Remedies’ arm commences commercial production of Pharmaceutical Intermediates 26 Mar, 9:58 AM Indoco Remedies gets nod to purchase land in Mumbai 12 Mar, 5:11 PM Indoco Remedies informs about press release 2 Mar, 12:18 PM Indoco Remedies’ arm starts commercial production of oral care products 2 Mar, 11:36 AM Indoco Remedies informs about newspaper publication 24 Jan, 4:35 PM Indoco Remedies - Quaterly Results 23 Jan, 12:29 PM Indoco Remedies - Quaterly Results 23 Jan, 12:29 PM Indoco Remedies - Quaterly Results 23 Jan, 12:29 PM Indoco Remedies gets EIR for Goa manufacturing facility from USFDA 18 Jan, 5:11 PM Indoco Remedies informs about receipt of establishment inspection report 18 Jan, 5:05 PM Indoco Remedies receives USFDA’s approval for Canagliflozin Tablets 6 Dec, 3:27 PM Indoco Remedies informs about press release 20 Oct, 2:51 PM Indoco Remedies informs about outcome of board meeting 19 Oct, 3:13 PM Indoco Remedies informs about issuance of corporate guarantee 19 Oct, 2:17 PM Indoco Remedies - Quaterly Results 19 Oct, 12:12 PM Indoco Remedies - Quaterly Results 19 Oct, 12:12 PM

Indoco Remedies Stock Price Analysis and Quick Research Report. Is Indoco Remedies an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Indoco Remedies and its performance over the period of time. Indoco Remedies stock price today is Rs 339.95.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Indoco Remedies cash from the operating activity was Rs 176.7844 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Indoco Remedies has a Debt to Equity ratio of 0.4424 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Indoco Remedies , the EPS growth was -17.5166 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Indoco Remedies has OPM of 13.9655633485036 % which is a bad sign for profitability.
     
  • ROE: Indoco Remedies have a average ROE of 10.8531 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Indoco Remedies is Rs 339.95. One can use valuation calculators of ticker to know if Indoco Remedies share price is undervalued or overvalued.
Last Updated on:
Brief about Indoco Remedies

Indoco Remedies Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Indoco Remedies Ltd. is a renowned pharmaceutical company with a strong presence in both domestic and international markets. With a legacy spanning several decades, the company has established itself as a key player in the pharmaceutical industry. Indoco Remedies Ltd. is known for its commitment to quality and innovation, and it operates across various therapeutic segments such as cardiovascular, anti-infectives, pain management, and more.

Indoco Remedies Ltd. - Share Price

The share price of Indoco Remedies Ltd. reflects the market's perception of the company's value and potential. Investors keen on analyzing the stock can track the share price using our pre-built screening tool, which provides real-time updates and historical data. By monitoring the share price, investors can identify trends, patterns, and potential buying or selling opportunities.

Indoco Remedies Ltd. - Balance Sheet

The balance sheet of Indoco Remedies Ltd. is a crucial financial statement that provides insights into the company's financial position. Investors can examine the company's assets, liabilities, and equity recorded on the balance sheet. To aid in the stock analysis process, our website offers premium features such as fair value calculations using tools like DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Indoco Remedies Ltd. - Annual Report

The annual report of Indoco Remedies Ltd. offers a comprehensive overview of the company's performance and achievements over the past year. It provides detailed information on the company's financials, operations, strategic initiatives, and future outlook. Investors can download the annual report from our website to gain an in-depth understanding of Indoco Remedies Ltd.'s progress and prospects.

Indoco Remedies Ltd. - Dividend

Dividends are an important consideration for long-term stock investors. Indoco Remedies Ltd. has a track record of rewarding its shareholders through regular dividend payouts. By analyzing the company's dividend history and policies, investors can gauge the company's commitment to sharing profits with its shareholders.

Indoco Remedies Ltd. - Quarterly Result

Keeping track of Indoco Remedies Ltd.'s quarterly results is essential for investors looking for timely and relevant information. Our website provides access to the company's quarterly reports, allowing investors to assess the company's performance, revenue, and profitability on a regular basis. Combining these reports with our pre-built screening tools can facilitate effective stock analysis.

Indoco Remedies Ltd. - Stock Price

Indoco Remedies Ltd.'s stock price is a dynamic indicator of market sentiment and investor perception. By analyzing historical stock price data and monitoring market trends, investors can identify potential trading opportunities. Our website offers real-time stock price updates, interactive price charts, and news to help investors make informed decisions.

Indoco Remedies Ltd. - Price Chart

Visual representation of Indoco Remedies Ltd.'s stock price movements can be insightful for investors. Our website features interactive price charts that enable users to track historical price trends, identify patterns, and analyze market behavior. Combined with our pre-built screening tools, investors can leverage price charts to enhance their stock analysis and decision-making.

Indoco Remedies Ltd. - News

Staying updated with the latest news and developments surrounding Indoco Remedies Ltd. is crucial for informed decision-making. Our website curates news articles and press releases related to the company, enabling investors to stay on top of industry trends, regulatory changes, product launches, and other market influences. Accessing relevant news can provide valuable insights for stock analysis.

Indoco Remedies Ltd. - Concall Transcripts

Concall transcripts offer detailed records of earnings conference calls conducted by Indoco Remedies Ltd. By accessing these transcripts through our website, investors gain access to management discussions, insights, and future guidance. These insights combined with our pre-built screening tools can enhance stock analysis and aid in understanding the company's strategic outlook.

Indoco Remedies Ltd. - Investor Presentations

Investor presentations provide a comprehensive overview of Indoco Remedies Ltd.'s business strategies, financial performance, and growth potential. By studying investor presentations available for download on our website, investors can gain deeper insights into the company's value proposition, market positioning, and future plans. Access to these presentations enhances the stock analysis process.

Indoco Remedies Ltd. - Promoters

Indoco Remedies Ltd. owes its success to its dedicated promoters. The promoters play a significant role in shaping the company's growth and strategy. Investors can evaluate the credibility and track record of the promoters to gain insights into the company's leadership and long-term vision.

Indoco Remedies Ltd. - Shareholders

Understanding the shareholders and their holdings in Indoco Remedies Ltd. can provide insights into the company's ownership structure and potential influence. Investors can analyze the shareholding patterns and identify key stakeholders who have a significant interest in the company. Such analysis can aid in evaluating the company's stability and potential for growth.

Remember, for detailed financial data points, numbers, and analyses, we recommend referring to the downloadable annual reports, concall transcripts, investor presentations, credit ratings, and research reports available on our website. Our premium features, such as fair value calculation tools, can further enhance your stock analysis. Stay abreast of the latest news, track the share price, and leverage our pre-built screening tools for a comprehensive analysis of Indoco Remedies Ltd.'s stock.

Read More
X